Your browser doesn't support javascript.
loading
Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 1244-1249, 2010.
Artigo em Chinês | WPRIM | ID: wpr-332384
ABSTRACT
Objective of this study was to evaluate the effectiveness and safety of autologous cytokine induced killer (CIK) cells combined with IL-2 in treatment of elderly patients with B-cell malignant lymphoma. Peripheral blood mononuclear cells (PBMNC) were isolated from 9 elderly patients with B-cell malignant lymphoma, and then induced into CIK cells by IFN-γ, IL-2 and monoclonal antibody (mAb) against CD3. The autologous CIK cells [(2-3)×10(9)] thus obtained were infused back to individual patients, then followed by subcutaneous injection of IL-2 at single daily dose of 1×10(4) U/day for 10 consecutive days. The regimen was repeated every 4 weeks and total 64 cycles of CIK cell transfusion were completed. The changes in cellular immune function, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life and survival time were assessed. 7 patients received 8 cycles of CIK cell infusion, and 4 cycles were completed in 2 patients. The results showed that no adverse reaction was observed in all above mentioned patients. The percentages of CD3+, CD3+CD8+ and CD3+CD56+ increased significantly (p<0.05), and serum levels of β2-microglobulin and LDH were markedly decreased (p<0.05) after autologous CIK cell transfusion. The lymphoma symptoms were relieved with quality of life obviously elevated (p<0.01) in all patients. Complete remission was seen in 8 patients. Though one patient received 8 cycles of CIK cell transfusion therapy and achieved transient very good partial remission, but he died of acute large-area myocardial infarction and persistent progression of lymphoma. In conclusion, regimen of autologous CIK cells combined with IL-2 is safe and effective for the therapy of elderly patients with B-cell malignant lymphoma.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Células Matadoras Naturais / Imunoterapia Adotiva / Linfoma de Células B / Interleucina-2 / Resultado do Tratamento / Usos Terapêuticos / Alergia e Imunologia / Células Matadoras Induzidas por Citocinas Limite: Idoso / Aged80 / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2010 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Terapêutica / Células Matadoras Naturais / Imunoterapia Adotiva / Linfoma de Células B / Interleucina-2 / Resultado do Tratamento / Usos Terapêuticos / Alergia e Imunologia / Células Matadoras Induzidas por Citocinas Limite: Idoso / Aged80 / Feminino / Humanos / Masculino Idioma: Chinês Revista: Journal of Experimental Hematology Ano de publicação: 2010 Tipo de documento: Artigo